GlassScriptPhysician profile
Sandeep Bhargava
NPI 1437109741
$7,595.79
in general payments reported to CMS, 2019-2025
36 companies · $2,364 in 2025
The $2,364 reported for 2025 was more than what a typical Transplant Hepatology provider received nationally (typical 2025 total: $508).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,061 · 2020: $560 · 2021: $392 · 2022: $399 · 2023: $741 · 2024: $2,078 · 2025: $2,364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,332 · Travel and Lodging: $841 · Education: $10.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,331.76 |
| Travel and Lodging | $841.15 |
| Education | $10.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,571.21 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Boston Scientific Corporation | $1,088.14 | 2019-2025 | Spyglass, General - Therapies, General - Hemostasis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $826.55 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $517.86 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $476.78 | 2019-2025 | Entyvio, Gattex |
| Pfizer INC. | $347.32 | 2019-2025 | |
| Braintree Laboratories, INC. | $248.36 | 2021-2025 | Suflave |
| Lilly USA, LLC | $231.41 | 2024-2025 | Omvoh |
| Gilead Sciences, INC. | $196.67 | 2019-2025 | |
| Abbott Laboratories | $139.55 | 2024 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $136.33 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $125.00 | 2020 | |
| Allergan, INC. | $68.57 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $54.83 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $50.80 | 2024-2025 | Dupixent |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $46.71 | 2019-2024 | Rebyota |
| Ardelyx, INC. | $45.14 | 2023-2024 | Ibsrela |
| Celgene Corporation | $43.56 | 2023 | Zeposia |
| Novo Nordisk INC | $40.69 | 2025 | Wegovy, Ozempic, Rybelsus |
| Daiichi Sankyo INC. | $39.92 | 2020 | |
| Madrigal Pharmaceuticals | $35.23 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $27.48 | 2019-2020 | |
| Exact Sciences Corporation | $22.63 | 2025 | Cologuard Collection Kit |
| Genzyme Corporation | $19.70 | 2024 | |
| Corcept Therapeutics | $18.80 | 2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $17.82 | 2025 | |
| Xeris Pharmaceuticals, INC. | $17.75 | 2025 | Recorlev |
| Covidien LP | $16.53 | 2019 | |
| Amgen INC. | $16.45 | 2025 | |
| Celltrion USA INC. | $16.28 | 2025 | Vegzelma |
| Kyowa Kirin, INC. | $16.25 | 2025 | |
| Amphastar Pharmaceuticals, INC. | $15.67 | 2025 | |
| Capsovision, INC. | $15.33 | 2024 | Capsocam Plus |
| Cook Medical LLC | $15.17 | 2021 | |
| Ucb, INC. | $15.00 | 2019 | |
| Shire North American Group INC | $14.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandeep Bhargava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.